SCHEMBL303812

SCHEMBL303812

O=[N+]([O-])c1cc2c(cc1Cl)NCCO2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.44
ALDH1A1 P00352 6/20 0.41
GAA P10253 2/20 0.41
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
ATM Q13315 1/20 0.39
MAPK1 P28482 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 1/20 0.38
VCAM1 P19320 2/20 0.37
CYP3A4 P08684 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19030024 0.85 MAPT (0.42) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL31451466 0.82 ALDH1A1 (0.48) MAPTALDH1A1GAAHSD17B10KDM4E
SCHEMBL14174533 0.79 ALDH1A1 (0.48) MAPTALDH1A1GAAHSD17B10KDM4E
SCHEMBL19030215 0.79 MAPT (0.41) MAPTALDH1A1GAAHSD17B10KDM4E
SCHEMBL108526 0.79 MAPT (0.64) MAPTALDH1A1GAAHSD17B10KDM4E
SCHEMBL10928322 0.79 MAPT (0.68) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL25387459 0.78 MAPT (0.44) MAPTALDH1A1GAAHSD17B10KDM4E
SCHEMBL28831801 0.78 ALDH1A1 (0.42) MAPTALDH1A1GAAHSD17B10KDM4E
SCHEMBL31451405 0.78 AR (0.51) MAPTALDH1A1GAAHSD17B10KDM4E
SCHEMBL27435131 0.78 ALDH1A1 (0.52) MAPTALDH1A1GAAHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093238-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-01-10 US disclosed
US-20100069361-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069361-A1 Fused Thiazole Derivatives as Kinase Inhibitors JAK1, MTOR, MOK MAPT 1997/4885ALDH1A1 1714/4885GAA 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.